Oruka Therapeutics reported Phase 2a results for its long-acting IL-23 monoclonal antibody ORKA-001 in plaque psoriasis, with 40 of 63 patients achieving PASI 100 at 16 weeks and 83% reaching PASI 90. The company said updated exposure analyses support an injection schedule that could enable dosing once per year. Analysts and investors are watching durability and quality-of-life outcomes, which the company indicated are pending relative to the early skin-clearance efficacy signal. Oruka positioned the program as potentially differentiated versus marketed IL-23 competitors that require more frequent dosing. If longer-term data confirm remission depth and durability, ORKA-001 could become a competitive option in a psoriasis market dominated by established IL-23 therapies.